Academic Journal
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer
| العنوان: | Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer |
|---|---|
| المؤلفون: | Alan-Selcuk, N., Beydagi, G., Demirci, E., Ocak, M., Celik, S., Oven, B.B., Toklu, T. |
| بيانات النشر: | Society of Nuclear Medicine Inc. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | actinium-targeted a-therapy, prostate cancer, PSMA, [177Lu]Lu-PSMA, [225Ac]Ac-PSMA, antiandrogen, dipeptide, lutetium, prostate specific antigen, radiopharmaceutical agent, single heterocyclic rings, aged, castration resistant prostate cancer, diagnostic imaging, human, male, middle aged, positron emission tomography-computed tomography, retrospective study, treatment outcome, Androgen Antagonists, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Positron Emission Tomography Computed Tomography, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Radiopharmaceuticals |
| الوصف: | For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC) who do not respond to [177Lu]Lu-PSMA therapy, there are limited treatment options. Clinical results obtained with [225Ac]Ac-PSMA are promising. We retrospectively analyzed the outcomes of patients treated with [225Ac]Ac-PSMA between December 2018 and October 2022. Methods: We evaluated the treatment results of 23 patients (mean age, 70.3 6 8.8 y) with mCRPC who were refractory to treatment with [177Lu]Lu-PSMA (2–9 cycles). The safety profile was assessed according to Common Technology Criteria for Adverse Events version 5.0. Treatment efficacy was assessed using prostate-specific membrane antigen PET progression criteria and prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 2 criteria after the first cycle of [225Ac]Ac-PSMA treatment. Results: All patients received androgen-deprivation therapy, whereas 22 (96%) and 19 (83%) patients received chemotherapy and second-generation antiandrogen therapy, respectively. One patient received 4 cycles, 2 received 3 cycles, 8 received 2 cycles, and 12 received 1 cycle of [225Ac]Ac-PSMA. The median interval between cycles was 13 wk (range, 8–28 wk). [225Ac]Ac-PSMA was administered with a mean activity of 7.6 MBq (range, 6.2–10.0 MBq) in each cycle. Patients were at an advanced stage of disease, and tumor burden was very high. Although the best PSA response was observed in 5 patients (26%) after [225Ac]Ac-PSMA treatment, there was at least some level of decline in PSA observed in 11 patients (58%; n 5 19). Treatment response was assessed in patients who underwent [68Ga]Ga-PSMA PET/CT imaging. After the first cycle of treatment (n 5 18), 50% of patients (n 5 9) showed disease progression according to prostate-specific membrane antigen PET progression criteria, and the disease control rate was calculated to be 50%. Median progression-free survival was 3.1 mo, and median overall survival was 7.7 mo. Grade 3 hematologic toxicity occurred in 1 patient, and ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 01615505 |
| Relation: | Journal of Nuclear Medicine; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.2967/jnumed.123.265546; https://hdl.handle.net/20.500.12831/17935; 64; 10; 1574; 1580; 2-s2.0-85173556660 |
| DOI: | 10.2967/jnumed.123.265546 |
| الاتاحة: | https://doi.org/10.2967/jnumed.123.265546 https://hdl.handle.net/20.500.12831/17935 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.FCBA886C |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 01615505 |
|---|---|
| DOI: | 10.2967/jnumed.123.265546 |